Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Homology Medicines, Inc. FIXX
$1.00
+$0 (0.48%)
На 18:01, 12 мая 2023
+170.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
57528944.00000000
-
week52high
3.30
-
week52low
0.86
-
Revenue
3208000
-
P/E TTM
-531
-
Beta
-0.06574300
-
EPS
-0.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Neutral | Neutral | 16 авг 2022 г. |
| Chardan Capital | Buy | Buy | 16 авг 2022 г. |
| BTIG | Buy | Buy | 16 авг 2022 г. |
| Credit Suisse | Neutral | Neutral | 17 мая 2022 г. |
| Credit Suisse | Neutral | 28 апр 2022 г. | |
| Baird | Outperform | Outperform | 31 авг 2022 г. |
| Chardan Capital | Buy | Buy | 17 ноя 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| TZIANABOS ARTHUR | D | 108395 | 10616 | 09 янв 2023 г. |
| Seymour Albert | D | 143166 | 3620 | 09 янв 2023 г. |
| Smith W Bradford | D | 14219 | 3729 | 09 янв 2023 г. |
| Alloway Paul | D | 20103 | 3090 | 09 янв 2023 г. |
| Blum Michael Lee | D | 13538 | 2454 | 09 янв 2023 г. |
| Alloway Paul | D | 10720 | 5280 | 01 янв 2023 г. |
| Alloway Paul | D | 4420 | 4290 | 01 янв 2023 г. |
| Alloway Paul | A | 23193 | 5280 | 01 янв 2023 г. |
| Alloway Paul | A | 17913 | 4290 | 01 янв 2023 г. |
| Smith W Bradford | D | 14070 | 6930 | 01 янв 2023 г. |
Новостная лента
Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Homology Medicines (FIXX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.20 per share a year ago.
Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 19:49
Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050%
PennyStocks
17 ноя 2022 г. в 12:02
Analysts say these are penny stocks to buy but do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 1,050% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates
Zacks Investment Research
15 авг 2022 г. в 19:33
Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
GlobeNewsWire
29 июн 2022 г. в 08:00
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: